7101-51-1COC(=O)[C@@H](N)Cc1ccc(O)c(O)c1XBBDACCLCFWBSI-ZETCQYMHSA-NMelevodopa is a tyrosine derivative.
7101-51-1DTXSID9048433CHEMBL1328898CHEBI:134880Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
N - Nervous system
QN - Nervous system
DescriptionCHF-1301 was launched as an injection in Italy for the treatment of patients with Parkinson's disease, particularly those with complications in their clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the immediate precursor of dopamine. Thus, this prodrug is more soluble in water at physiological pH, better absorbed and slowly transformed into levodopa in vivo; it consequently improves the duration of action and prevents the rapid fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa (on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF- 1301 significantly improves the onset and the stability of the'response.
DefinitionChEBI: Melevodopa is a tyrosine derivative.
Loading…